|
gptkbp:instanceOf
|
gptkb:drug
gptkb:benzodiazepine
|
|
gptkbp:approvedBy
|
gptkb:FDA
1963
|
|
gptkbp:ATCCode
|
N05BA01
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
injectable solution
rectal gel
|
|
gptkbp:brand
|
gptkb:Diastat
gptkb:Diazemuls
gptkb:Valium
|
|
gptkbp:CASNumber
|
439-14-5
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
sleep apnea syndrome
severe hepatic insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Leo_Sternbach
|
|
gptkbp:discoveredIn
|
1963
|
|
gptkbp:eliminationHalfLife
|
20-100 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C16H13ClN2O
|
|
gptkbp:KEGGID
|
gptkb:D00293
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABA-A receptor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
284.7 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB00829
2911
3016
CHEMBL26
49575
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
rectal
|
|
gptkbp:sideEffect
|
fatigue
muscle weakness
drowsiness
impaired coordination
dependence
|
|
gptkbp:UNII
|
Q3JTX2Q7TU
|
|
gptkbp:usedFor
|
anxiety disorders
seizure disorders
muscle spasms
alcohol withdrawal
sedation before medical procedures
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:4-aminobutanoic_acid
gptkb:omeprazole
gptkb:benzodiazepines
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
diazepam
|